Adverse drug events · people with ADHD and epilepsy
1 finding from 1 review
Number of participants with any serious adverse events · primary progressive multiple sclerosis
Ocrelizumab showed no clear difference in number of participants with any serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Number of adverse events requiring discontinuation of treatment ‐ not reported · primary progressive multiple sclerosis
Ocrelizumab showed no clear difference in number of participants experiencing treatment discontinuation caused… compared with placebo (low certainty).
1 finding from 1 review
Number of participants with gadolinium‐enhancing T1 lesions on MRI · primary progressive multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
Number of participants with new or enlarging T2‐hyperintense lesions on MRI · primary progressive multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
Number of participants experiencing disability progression · primary progressive multiple sclerosis
Ocrelizumab may leads to lower number of participants experiencing disability progression compared with placebo (low certainty).
1 finding from 1 review
Number of participants with any adverse events · primary progressive multiple sclerosis
Ocrelizumab probably leads to higher number of participants with any adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Exacerbation frequency · people with bronchiectasis
14 days on/off antibiotic regimen probably leads to lower exacerbation frequency compared with 14 days on/off placebo regimen (moderate certainty).
2 findings from 1 review
RR 0.75 [0.61, 0.93]
Studies not reported
Moderate
no estimate extracted
Studies not reported
Moderate
Serious adverse events · people with bronchiectasis
28 days on/off antibiotic regimen showed no clear difference in serious adverse events compared with 28 days on/off placebo regimen (low certainty).
1 finding from 1 review
OR 1 [0.68, 1.46]
Studies not reported
Low
Antibiotic resistance · people with bronchiectasis
28 days on/off antibiotic regimen leads to higher antibiotic resistance compared with 28 days on/off placebo regimen (high certainty).
1 finding from 1 review
OR 2.2 [1.42, 3.42]
Studies not reported
High
Pulmonary exacerbations: number of hospitalisations due to respiratory exacerbations · people with bronchiectasis
28 days on/off antibiotic regimen showed no clear difference in hospitalisation for pulmonary exacerbations compared with 28 days on/off placebo regimen (high certainty).
1 finding from 1 review
OR 0.79 [0.49, 1.29]
Studies not reported
High
Health‐related quality of life · people with bronchiectasis
2 findings from 1 review
no estimate extracted
Studies not reported
Moderate
no estimate extracted
Studies not reported
Low
Serious adverse events · people with bronchiectasis
14 days on/off antibiotic regimen showed no clear difference in serious adverse events compared with 14 days on/off placebo regimen (high certainty).
1 finding from 1 review
OR 0.92 [0.63, 1.33]
Studies not reported
High
Antibiotic resistance · people with bronchiectasis
14 days on/off antibiotic regimen leads to higher antibiotic resistance compared with 14 days on/off placebo regimen (high certainty).
1 finding from 1 review
OR 2.14 [1.36, 3.35]
Studies not reported
High
Frequency of hospital admissions for pulmonary exacerbations ‐ not measured · people with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with bronchiectasis
2 findings from 1 review
no estimate extracted
Studies not reported
High
no estimate extracted
Studies not reported
Moderate
Exacerbation frequency · people with bronchiectasis
28 days on/off antibiotic regimen showed no clear difference in exacerbation frequency compared with 28 days on/off placebo regimen (high certainty).
2 findings from 1 review
RR 0.92 [0.82, 1.02]
Studies not reported
High
no estimate extracted
Studies not reported
Low
Weight: clinically important change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Weight: clinically important change in BMI (kg/m2) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Change in BMI · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review